The CDC and FDA announced on Tuesday that healthcare providers should quit administrating the Johnson & Johnson vaccine while reports of extremely rare blood clotting are investigated.
Six women between the ages of 18 and 48 allegedly developed blood clots after receiving the vaccine. One has died while another is in critical condition says the FDA.
“We are recommending this pause while we work together to fully understand these events, and also so we can get information out to health care providers and vaccine recipients,” said Dr. Janet Woodcock, acting FDA commissioner, during a briefing Tuesday.
The review is expected to be completed quickly, possibly within a few days, according to officials.
The blood clotting is extremely rate. Only six people out of nearly 6.8 million people who have received the vaccine have developed the complication. None of the other vaccines have been confirmed to cause issues.
“We continue to work closely with experts and regulators to assess the data and support the open communication of this information to healthcare professionals and the public,” said Johnson & Johnson.
Jeff Zients, the White House Covid-19 Response Coordinator, says that this pause “will not have a significant impact” on the White House’s vaccination plans.